MJR-35 phase 3 study to investigate the efficacy and safety in patients with adenomyosis (a multicenter, randomized, double-blind, placebo-controlled, parallel-group study)

Trial Profile

MJR-35 phase 3 study to investigate the efficacy and safety in patients with adenomyosis (a multicenter, randomized, double-blind, placebo-controlled, parallel-group study)

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Dienogest (Primary)
  • Indications Adenomyosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Mochida Pharmaceutical
  • Most Recent Events

    • 11 Sep 2017 Primary endpoint (Decrease from baseline in the pain score and visual analogue scale at the end of the treatment) has been met, as per the results published in the Fertility and Sterility.
    • 11 Sep 2017 Results assessing efficacy and safety of dienogest, published in the Fertility and Sterility.
    • 24 Nov 2015 Status changed from not yet recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top